BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Seoul、大韩民国、135-710
- Samsung Medical Center
-
Seoul、大韩民国、110-744
- Seoul National University Hospital
-
-
-
-
-
Berlin、德国、12200
- Charité - Universitätsmedizin Berlin
-
Dresden、德国、01307
- Universitätsklinikum Carl Gustav Carus Dresden
-
Frankfurt am Main、德国、60590
- Universitätsklinikum Frankfurt
-
Göttingen、德国、37075
- Universitätsmedizin Göttingen, Georg-August-Universität
-
Hamburg、德国、20099
- Asklepios Klinik St. Georg
-
Heidelberg、德国、69120
- Universitatsklinikum Heidelberg
-
Jena、德国、07740
- Universitatsklinikum Jena
-
Ulm、德国、89081
- Universitätsklinikum Ulm
-
-
-
-
-
Marseille Cedex 09、法国、13273
- INS Paoli-Calmettes
-
Pierre Bénite、法国、69495
- HOP Lyon Sud
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria:
- Patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin (mature B cell lymphoma according to WHO) not considered candidates for intensive anti-lymphoma therapy
- Patients must have either aggressive NHL and received at least one prior anti-CD20 containing immunochemotherapy or indolent NHL and received anti-CD20 therapy and at least two prior therapies
- Measurable disease on computed tomography (CT) scan with involvement of one clearly demarcated lesion =2 cm or two or more clearly demarcated lesions of >1.5 cm at longest diameter (this criterion applies only for the expansion cohort)
- Relapse or progression of disease with an indication for therapy as per investigator's judgement
- Life expectancy of =3 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
Exclusion criteria:
- Primary central nervous system (CNS) lymphoma or known CNS involvement
- Prior history of malignancy other than a mature B cell neoplasm according to WHO classification (except basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the uterine cervix or breast treated with curative therapy) unless the subject has been free of disease and without treatment for at least 5 years
- Last chemotherapy <4 weeks prior to visit 1
- Last anti-CD20 therapy (non-radiolabelled) <4 weeks prior to visit 1
- Last corticosteroid <2 weeks prior to visit 1 unless the dose is less or equal of 10 mg/day prednisolone or equivalent
- High-dose therapy with stem cell support <6 months prior to visit 1
- Radio-immunotherapy <3 months prior to visit 1
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 介入模型：顺序分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Patients with relapsed or refractory NHL
Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments
|
Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Determination of the Maximum Tolerated Dose (MTD) Based on the Occurrence of Dose-limiting Toxicity (DLT) in First Cycle in Caucasian Patients
大体时间：From the first administration of trial medication to 7 days after the second administration, upto 36 days
|
The primary objective of the dose-escalation part of this study was to determine the MTD of BI 836826 in caucasian patients.
The MTD was to be defined on the basis of DLTs observed during the first 2 weeks of the 1st treatment course.
In case of a delay of the second administration, evaluation of DLT was to be prolonged to 7 days after the second administration..
A DLT was defined as any drug-related non-haematological Adverse event (AE) of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or higher, except Infusion-related reaction (IRRs) associated with the administration of BI 836826.
|
From the first administration of trial medication to 7 days after the second administration, upto 36 days
|
|
Number of Subjects With Dose Limiting Toxicities (DLT) in First Cycle in Caucasian Patients
大体时间：From the first administration of trial medication to 7 days after the second administration, up to 36 days
|
Number of subjects with Dose Limiting Toxicities (DLT) in first Cycle during the MTD evaluation period in caucasian patients with relapsed or refractory Non-Hodgkin lymphoma (NHL).
|
From the first administration of trial medication to 7 days after the second administration, up to 36 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Tumour Size Reduction
大体时间：Computed tomography (CT) scan performed at screening, at Week 13, and at Week 25.
|
Tumour size reduction (lymph nodes, spleen, & liver nodules) defined as best percentage change from baseline in sum of products of diameter (SPD).
Negative value represents decrease in tumour size, & positive value represents an increase in size.
The tumour size of lymph nodes was to be measured as SPD of 2 perpendicular dimensions for up to 6 indicator lesions identified at baseline CT scan.
Spleen & liver were to be described if considered enlarged at baseline by physical examination or CT scan.
If nodules present in spleen &/or liver, was to be measured in 2 perpendicular dimensions.
Median, 25th & 75th percentiles are calculated from unadjusted Kaplan-Meier curve for each treatment cohort.
|
Computed tomography (CT) scan performed at screening, at Week 13, and at Week 25.
|
|
Best Overall Response Based on All Assessment
大体时间：Screening, Week 1, Week 4, Week 7, Week 8, Week 11, Week 14, Week 15, Week 18 and at End of Treatment (EOT)
|
Best overall response was best response at any of CT scans and investigator assesment (incase the recent CT scan was not available). Response was assessed as follow according to the Standardized or Revised Response Criteria for Malignant Lymphoma from 1999.:
|
Screening, Week 1, Week 4, Week 7, Week 8, Week 11, Week 14, Week 15, Week 18 and at End of Treatment (EOT)
|
|
Best Overall Response Based on Imaging Data
大体时间：Computed tomography (CT) scan performed at screening, at Week 13, and at Week 25.
|
Best overall response based on imaging data. Response was assessed as follow according to the Standardized or Revised Response Criteria for Malignant Lymphoma from 1999.:
|
Computed tomography (CT) scan performed at screening, at Week 13, and at Week 25.
|
|
Progression Free Survival (PFS)
大体时间：from first treatment until disease progression or death from any cause, up to 12 months.
|
PFS was defined as the time from first treatment with BI 836826 until disease progression or death from any cause. For disease progression one of the following criteria was required: • Any new lesion >1.5 centimeter (cm) in any axis • Increase of ≥50% from nadir in sum of product of diameter of any previously involved nodes or single nodes or the size of hepatic or splenic nodules. A lymph node with a diameter of the short axis of <1 cm had to increase by ≥50% and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis • Increase of ≥50% in the longest diameter of any single previously identified node >1 cm in its short axis. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment cohort. |
from first treatment until disease progression or death from any cause, up to 12 months.
|
|
Failure Free Survival (FFS)
大体时间：from first treatment with BI 836826 until objective disease progression, death, or start of next NHL therapy, up to 12 months.
|
FFS was defined as the time from first treatment with BI 836826 until objective disease progression, death, or start of next Non-Hodgkin lymphoma (NHL) therapy.For disease progression one of the following criteria was required: • Any new lesion >1.5 centimeter (cm) in any axis • Increase of ≥50% from nadir in sum of product of diameter of any previously involved nodes or single nodes or the size of hepatic or splenic nodules. A lymph node with a diameter of the short axis of <1 cm had to increase by ≥50% and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis • Increase of ≥50% in the longest diameter of any single previously identified node >1 cm in its short axis. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment cohort. |
from first treatment with BI 836826 until objective disease progression, death, or start of next NHL therapy, up to 12 months.
|
合作者和调查者
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.